Navigation Links
Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
Date:3/31/2008

The Company's cardiovascular medicine clinical trial program includes ONTARGET, PRoFESS, TRANSCEND and other studies involving more than 75,000 patients in more than 40 countries. These studies were designed to evaluate ways to reduce the risk of damaging events in the heart, brain and other organs due to cardiovascular disease and to uncover new treatment strategies that improve patient outcomes and care.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2006, Boehringer Ingelheim posted net sales of US $13.3 billion (10.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit http://us.boehringer-ingelheim.com .

About Micardis(R) (telmisartan)

Telmisartan is marketed in the United States by Boehringer Ingelheim as MICARDIS(R) tablets. MICARDIS is indicated for the treatment of hypertension.

USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, MICARDIS tablets should be discontinued as soon as possible (see WARNINGS,
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
2. Viatronix V3D-Colon Utilized in Another Landmark Study
3. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
4. Hospital Launches Landmark Emergency Medicine Project
5. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014  - ... Today Lincor announced general availability of MediaLINC ... delivers a range of education, entertainment and clinical content ... (Logo: http://photos.prnewswire.com/prnh/20140822/702945) , " Lincor ... care patient engagement to bedside smart devices, " comments ...
(Date:8/22/2014)... Aug. 22, 2014  Cannabis Science, Inc. (OTC: ... drug development and related consulting, is pleased to ... medical cannabis conference taking place at the Faculty ... , on October 22, 2014.  The multilingual conference ... as researchers, health professionals, and patients, to discuss ...
(Date:8/22/2014)... Aug. 22, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... William E. Saxelby , its President and Chief Executive ... Executive Officer and as a member of the Board ... will be replaced on an interim basis by ...
Breaking Medicine Technology:Lincor Unveils Next Generation TV-based Patient Engagement Solution 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3Landauer, Inc. Announces Executive Management Change 2
... 15, 2011 PDI, Inc. (Nasdaq: ... promotional outsource services to established and emerging health care ... partnership with Qforma, the leading provider of advanced analytics ... Through this agreement, PDI will gain access ...
... REDWOOD CITY, Calif., March 15, 2011 – Ingenuity® ... solutions for life science researchers, today announced new ... in IPA®. Processed RNA-Seq datasets can now be ... context of pathways and diseases for a rich ...
Cached Medicine Technology:PDI Announces Exclusive Partnership With Qforma, Leading Provider of Advanced Analytics for Health Sciences Industry 2Ingenuity Announces RNA-Sequencing Workflow Support and First-of-Its-Kind microRNA Filtering Capability With Latest Release of IPA 2Ingenuity Announces RNA-Sequencing Workflow Support and First-of-Its-Kind microRNA Filtering Capability With Latest Release of IPA 3
(Date:8/22/2014)... The ALS Association, along with its Western Pennsylvania ... Health Network as a Certified Treatment Center of ... (AGH), is the only ALS treatment program in western ... highest levels of established national standards of care in ... to as Lou Gehrig’s Disease. , Allegheny Health Network’ ...
(Date:8/22/2014)... This funding was made through an additional ... Therapeutics, Inc. in the form of a convertible promissory ... collaborate with Saneron on several fronts to enable the ... to regenerative therapies using cord blood to ... Chairman and Co-CEO of Cryo-Cell, stated. He continued, ...
(Date:8/22/2014)... Human induced pluripotent stem cells (hiPSCs) have ... they can be coaxed to turn into specific cells; ... They sometimes mutate, develop into tumors or produce other ... published in STEM CELLS Translational Medicine, researchers appear to ... the material used to reprogram the stem cell after ...
(Date:8/22/2014)... 22, 2014 The New Jersey ... Rutgers, the State University of New Jersey has joined ... media organization, to educate young people about health and ... the strengths of both organizations. , The partnership will ... communications fellowship program, and video communications. ChopChop Magazine ...
(Date:8/22/2014)... air in American cities is getting safer to breathe, ... progress has been made in reducing levels of harmful ... said in a news release. Since 1990, there ... from human sources such as coal-fired plants, a 66 ... in lead, which harms brain development in children. ...
Breaking Medicine News(10 mins):Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 2Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 3Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 2Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 3Health News:Removing Programming Material After Inducing Stem Cells Could Improve Their Regeneration Ability 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 3Health News:Air in U.S. Cities Getting Cleaner, EPA Says 2
... Reporter , MONDAY, March 26 (HealthDay News) -- Here,s a ... who eat chocolate regularly are somewhat skinnier than folks who ... that chowing down on chocolate will melt off your excess ... modest difference in body mass, or it might be a ...
... honored with the Distinguished Sonographer Award during the 2012 ... at the JW Marriott Desert Ridge Resort and Spa ... Sonographer Award is a means of recognizing and honoring ... to the growth and development of medical ultrasound. ...
... Lisa Esposito HealthDay Reporter , THURSDAY, March ... initiative since the Medicare and Medicaid programs of the ... presidency, is about to face its biggest challenge. ... unprecedented six hours of arguments over three days on ...
... , MONDAY, March 26 (HealthDay News) -- ... leading cause of death among women in the United ... clinics, a new study suggests. Researchers from ... that heart screenings performed during visits to obstetrician/gynecologists could ...
... cancer researcher Professor Jane Visavader has been selected to ... The fellowship recognises Professor Visvader,s research over the past ... that can give rise to all types of cells ... which different types of breast cancer arise., Professor Visvader, ...
... offering in late March a new stereotactic radiosurgery ... available. The new imaging and radiosurgery ... fast and precise noninvasive image-guided radiation therapy. Radiosurgery ... with high precision to a tumor. "Radiosurgery ...
Cached Medicine News:Health News:Does Chocolate Help You Stay Slim? 2Health News:Does Chocolate Help You Stay Slim? 3Health News:Supreme Court Prepares to Tackle Affordable Care Act 2Health News:Supreme Court Prepares to Tackle Affordable Care Act 3Health News:Supreme Court Prepares to Tackle Affordable Care Act 4Health News:Supreme Court Prepares to Tackle Affordable Care Act 5Health News:Supreme Court Prepares to Tackle Affordable Care Act 6Health News:Ob/Gyn Visit a Good Time to Screen for Heart Disease: Study 2Health News:Professor Jane Visvader elected to Australian Academy of Science 2Health News:Cancer treatment system sculpts radiation beam to match shape of a tumor 2
... key challenges. Reducing costs while adjusting to ... Meeting ever-increasing expectations from more informed customers. ... with labor shortages. Providing value in managing ... theres targeted relief from a trusted partner ...
... The Roche Diagnostics Task Targeted ... state-of-the-art automation of pre- ... laboratories: decapping, sorting / archiving ... into bar code labeled secondary ...
... 20 years of experience in providing ... Life Sciences, the Freedom EVO platform ... for expansion according to future needs., ... Freedom EVOware, each system is equipped ...
... designed a flexible liquid handling system that ... three liquid handlers all on the same ... for targeted applications or custom-tailored to meet ... provide comprehensive systems that combine all the ...
Medicine Products: